Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells
Clinical Cancer Research2011Vol. 17(19), pp. 6192–6205
Citations Over TimeTop 10% of 2011 papers
Louisa von Baumgarten, David Brucker, Anca Tirniceru, Yvonne Kienast, Stefan Grau, Steffen Burgold, Jochen Herms, Frank Winkler
Abstract
Regression of glioma cells can occur independently from vascular regression, suggesting that high doses of bevacizumab have indirect anticancer cell properties in vivo.
Related Papers
- → Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications(2002)625 cited
- → Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications(2002)547 cited
- → Vasorin stimulates malignant progression and angiogenesis in glioma(2019)48 cited
- Effect of Bevacizumab on Angiogenesis and Glioma Growth Induced by Low Dose of ALA-PDT(2011)
- → Influence of bevacizumab on the invasion of glioma and the mechanism(2012)